EpistemisHydrochlorothiazide and Chlorthalidone
Common trade names: Diclotride, Nefrix, HCTZ Genfar (Hydrochlorothiazide); Higroton, Chlorthalidone MK (Chlorthalidone).
Mechanism
Pharmacological Class and Group
Antihypertensives and diuretics belonging to the class of Thiazidic Diuretics (Hydrochlorothiazide) and subtle thiazide-type diuretics (Chlorthalidone).
Mechanism of Action
The distal convoluted tubule (DTC) finely reabsorbs approximately 5% to 8% of the sodium load filtered by the glomerulus. This transport is mediated by an electroneutral coupled sodium and chloride co-transporter (NCC) located in the apical membrane of tubular cells.
NCC and Calciuria Co-transporter Blocking Mechanism
1. Selective inhibition of the apical NCC co-transporter: Hydrochlorothiazide and chlorthalidone are actively secreted into the tubular lumen by proximal organic anion transporters. Upon reaching the distal tubule, they competitively bind to the chloride binding site of the apical co-transporter NCC, blocking the coupled reabsorption of sodium and chloride:
Thiazide Co-transporter NCC ↑ Urinary excretion of Na+ and Cl-
2. Increased Active Calcium Reabsorption (Anticalciuric Effect): By blocking cellular sodium entry through the NCC transporter, intracellular sodium levels fall. This overstimulates the activity of the basolateral sodium-calcium exchanger (NCX1), which introduces three sodium ions into the cell in exchange for the expulsion of one calcium ion into the capillary interstitium, promoting the apical entry of calcium through the TRPV5 channels:
↓ [Na+] intracellular ↑ Basolateral NCX1 activity ↑ Net Ca2+ reabsorption
This effect significantly decreases urinary calcium excretion (calciuria), differentiating thiazides from loop diuretics (which promote calciuria).
3. Long-Term Direct Vasodilatory Effect: The initial antihypertensive effect is associated with volume reduction. However, in the long term, extracellular volume is partially normalized, and the persistent hypotensive effect of thiazides is due to a direct reduction in PVR mediated by the opening of calcium-activated potassium channels in vascular smooth muscle, decreasing local sympathetic reactivity.
Pharmacokinetics
Comparative Pharmacokinetics
- Hydrochlorothiazide: Oral bioavailability of 65% to 75%. It does not undergo known hepatic metabolism and is eliminated unchanged through the kidneys (active proximal secretion). It has a plasma elimination half-life of 6 to 15 hours, with a duration of its hypotensive effect of up to 12-24 hours based.
- Chlorthalidone: It has a bioavailability of 64%. It exhibits unique pharmacokinetics characterized by a high accumulation in erythrocytes, where it binds with extreme affinity to the enzyme carbonic anhydrase. This acts as a reservoir for sustained release of the drug into the capillary circulation. It has an extraordinarily long terminal elimination half-life of 40 to 60 hours, guaranteeing sustained blood pressure control of more than 24 hours (ideal for nighttime and early morning blood pressure coverage). Majority renal excretion.
Indicators and dose
Clinical Indications and Uses
- Systemic Arterial Hypertension: First line, especially chlorthalidone due to its prolonged half-life and greater potency demonstrated in reducing cardiovascular events (ALLHAT clinical trial).
- Idiopathic Hypercalciuria and Prevention of Calcium Lithiasis: To reduce the nucleation and impaction of calcium oxalate crystals in the urinary tract.
- Nephrogenic Diabetes Insipidus: Paradoxical effect that reduces total urinary flow by inducing a mild depletion of base volume that favors proximal compensatory reabsorption of free water.
- Mild to Moderate Edema: In patients with stable heart failure or underlying nephropathy.
Dosage and Clinical Adjustment
Hydrochlorothiazide:
- High Blood Pressure: Starting dose of 12.5 mg to 25 mg once daily orally in the morning. Doses greater than 25 mg do not offer greater hypotensive efficacy and increase the incidence of metabolic adverse effects.
- Renal Adjustment: Its use is not recommended if the eGFR is less than 30 mL/min/1.73 m².
Chlorthalidone:
- High Blood Pressure: Usual dose of 12.5 mg to 25 mg once a day. Recommended target maintenance dose of 25 mg per day.
Security
Absolute and Relative Contraindications
Absolute Contraindications
- Known hypersensitivity to thiazides or sulfonamides.
- Established anuria or underlying terminal renal failure.
- Renal Failure with eGFR < 30 mL/min/1.73 m²: Thiazides lose practically all their diuretic efficacy at this level (except for the specific use of metolazone or indapamide).
Relative Contraindications
- Gout or severe hyperuricemia (thiazides raise uric acid).
- Unstable diabetes mellitus (thiazides alter insulin secretion by inducing hypokalemia in beta cells).
- Previous basal hyponatremia.
Adverse Effects and Toxicity
- Metabolic Alterations (The "Four Hypo" and the "Four Hyper"):
- Orthostatic hypotension, severe hypokalemia, dilutional hyponatremia, and hypomagnesemia.
- Moderate hypercalcemia, hyperuricemia with triggering of gout crises, hyperglycemia (due to alteration in the ATP-dependent potassium channels of the pancreatic beta cell), and de novo transient hyperlipidemia.
- Erectile Dysfunction: Of multifactorial origin, more common with thiazides than with other antihypertensives.
Emergency Alert: Severe Dilutional Hyponatremia induced by Thiazides
Thiazidic diuretics block transport in the distal convoluted tubule, sparing the loop of Henle. This preserves intact the medullary water-concentrating capacity mediated by ADH in the collector. If the patient increases free water intake, the kidney greedily reabsorbs water while distal sodium excretion is forced, rapidly triggering severe dilutional hyponatremia:
Use of Thiazide + Free Water Intake Hyponatremia (Na+ < 120 mEq/L) Acute Cerebral Edema
This complication is more prevalent in older, thin women and during the first two weeks of treatment. It requires immediate suspension of the drug and strict restriction of free water or provision of hypertonic saline solutions in a controlled manner.
Relevant Drug Interactions
- NSAIDs: They block the synthesis of vasodilatory prostaglandins, attenuating the hypotensive effect of thiazides.
- Digoxin: Concomitant hypokalemia predisposes to serious arrhythmias due to digitalis toxicity.
- Oral Antidiabetics and Insulin: Thiazides reduce insulin secretion, so an increase in the doses of oral hypoglycemic agents may be required.
Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.
- System
- Cardiovascular
- Cluster
- Thiazidic and Thiazide Profile Diuretics